Dr. Scott T. Tagawa on PSMA-targeted agents in prostate cancer

Scott T. Tagawa, MD, discusses the emergence of PSMA-targeted agents in the field of prostate cancer. He draws specific attention to the targeted radioligand therapy 177Lu-PSMA-617 (LuPSMA) and the phase 2 TheraP trial, which showed that LuPSMA had stronger clinical activity with fewer grade 3/4 adverse events compared with cabazitaxel (Jevtana) in patients with metastatic castration-resistant prostate cancer (mCRPC). Subsequent to this interview, it was announced that in the phase 3 VISION trial, adding LuPSMA to best standard of care improved overall survival in patients with progressive PSMA-positive mCRPC.

Tagawa is a professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.